Leadership

Executive Team

 

Senior Leadership

 

Board of Directors

 

 

Executive Team
 

J. Kevin Buchi

Interim President, Chief Executive Officer and Director 

Mr. Buchi was appointed Interim President and Chief Executive Officer effective December 19, 2016. Mr. Buchi currently serves as President, Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation. Mr. Buchi intends to retire from his position as President and Chief Executive Officer of TetraLogic Pharmaceuticals at the end of the year commensurate with TetraLogic Pharmaceuticals’ previously announced asset sale to Medivir AB, which transaction is currently expected to close by December 31, 2016. Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012. Before joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva in October 2011. Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon’s Chief Executive Officer in December 2010. In addition to serving as a director of Impax and TetraLogic Pharmaceuticals, Mr. Buchi has since 2013 served as a director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia. He has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S. Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University.

Douglas S. Boothe

President, Impax Generics Division

Douglas S. Boothe joined Impax as President, Generics Division on August 1, 2016. Mr. Boothe previously served as Executive Vice President and General Manager with Perrigo Company Plc, where he had responsibility for US Pharmaceuticals, including Generics and Specialty. Mr. Boothe also served as Chief Executive Officer of Actavis, Inc. from August 2008 to December 2012 and as Executive Vice President and Chief Operating Officer from 2006 to 2008. Prior to Actavis, Mr. Boothe held various senior positions in strategic planning and business development for Alpharma Inc., Pharmacia Corporation, and Xerox Corporation, and recently served as a Director of the Generic Pharmaceutical Association. Mr. Boothe earned a Bachelor’s degree in mechanical & aerospace engineering from Princeton University and a Master of Business Administration from the University of Pennsylvania's Wharton School of Business.

Michael J. Nestor

President, Impax Specialty Pharma Division

Michael J. Nestor has served as President of our branded products division since March 2008. Before joining us, he was Chief Operating Officer of Piedmont Pharmaceuticals, a specialty pharmaceutical company, from July 2007 to March 2008. Prior to Piedmont, Mr. Nestor was CEO of NanoBio, a startup biopharmaceutical company from December 2004 to November 2006, prior to which he was employed by Alpharma, initially as President of its generic pharmaceutical business and later as President of its branded pharmaceutical business. Before Alpharma, he was President, International business at Banner Inc., a global contract manufacturing concern. Prior to Banner, Mr. Nestor spent 16 years at Lederle Laboratories / Wyeth holding increasing positions of responsibility including Vice President, Cardiovascular business, Vice President / General Manager of Lederle-Praxis Biologics, and Vice President of Wyeth-Lederle Vaccines and Pediatrics. Mr. Nestor has a Bachelor's degree in Business Administration from Middle Tennessee State University and a Master of Business Administration from Pepperdine University.

Jeffrey D. Nornhold

Senior Vice President, Technical Operations

Jeffrey D. Nornhold has served as our Senior Vice President of Technical Operations since April 2014, and is responsible for the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Senior Vice President, Global Quality Affairs since March 2011, and was responsible for establishing the foundation for a sustainable quality and compliance program. Jeff joined Impax from Watson Pharmaceuticals, Inc., (now Actavis) where he was the Vice President, Quality Operations - International, and was responsible for outside of the U.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While at Watson, he also served as Vice President U.S. Quality Operations leading the development and execution of quality initiatives for all U.S. sites. Prior to joining Watson in 2000, he held numerous leadership positions within the pharmaceuticals industry. He earned a Bachelor's degree in chemistry from Bowling Green State University and a Master of Business Administration from the University of Southern California Marshall School of Business.

Bryan M. Reasons

Senior Vice President, Finance and Chief Financial Officer

Bryan M. Reasons has served as our Senior Vice President, Finance and Chief Financial Officer since December 2012 and previously served as our Acting Chief Financial Officer from June 2012 to December 2012 and as our Vice President, Finance from January 2012 to June 2012. Prior to joining us in January 2012, Mr. Reasons served as Vice President, Finance, from January 2010 to November 2011 and as Vice President, Risk Management and General Auditor, from October 2005 to January 2010 at Cephalon, Inc., a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharamaceutical Industries Ltd., a generic pharmaceuticals company, he served as Vice President, Finance of Teva from November 2011 to January 2012. Prior to joining Cephalon, Mr. Reasons held various finance management positions at DuPont from 2003 to 2005 and served as senior manager at PricewaterhouseCoopers LLP from 1992 to 2003. Mr. Reasons has a Bachelor's degree in accounting from Pennsylvania State University and a Master of Business Administration from Widener University and is a certified public accountant.

Mark A. Schlossberg

Senior Vice President and General Counsel

Mark A. Schlossberg has served as our Senior Vice President, General Counsel and Corporate Secretary since May 2011. Prior to joining us, he served as Vice President, Associate General Counsel of Amgen Inc. from September 2004 to May 2011. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. He earned a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.

 

Senior Leadership
 

Goff Baker

Senior Vice President, Global Quality

Goff Baker serves as Senior Vice President, Global Quality. He has been instrumental in driving quality improvements, compliance initiatives and remediation efforts across our operations. He is responsible for the oversight and direction of all Impax Quality and Compliance functions supporting internal manufacturing and packaging operations as well as contract manufacturing operations. Goff joined Impax in August 2013 as Vice President, Quality Operations. Prior to joining Impax, Goff served as Vice President, Quality at Qualitest Pharmaceuticals, where he successfully led the organization into sustainable compliance while supporting the company's growth to become a top-5 U.S. generics manufacturing organization. Prior to Qualitest, he was Senior Director, QA/QC with Reliant Pharmaceuticals and with Mylan Technologies (a division of Mylan Laboratories) as Senior Group Leader, Research and Development. Goff holds a Bachelor’s degree in Chemistry from Georgetown University.

Suneel Gupta, Ph.D.

Chief Scientific Officer, Impax Specialty Pharma Division

Dr. Gupta joined Impax in Feb 2008 from ALZA/Johnson & Johnson, where he was most recently Senior Vice President. Dr. Gupta held several leadership positions with increasing responsibilities over almost 20 years at ALZA/JnJ. Dr. Gupta made significant contributions to development of several drug delivery based products. Dr. Gupta has worked across several therapeutic areas. His research interest focuses on the influence of rate and route of drug delivery to discover new indications, maximize clinical utility and/or effectiveness. He is often credited as the co-inventor of several drug delivery products. Before ALZA, Dr Gupta worked for about four years at Ciba Geigy (India) in scale-up and manufacturing of several products. Dr. Gupta did his Ph.D. from Univ. of Manchester and Post-Doc from University of California, San Francisco. Dr. Gupta is a coauthor on more than 200 research publications and co-inventor on more than 40 patents.

Vishal K. Gupta, Ph.D.

Chief Scientific Officer and Senior Vice President, R&D

Dr. Gupta joined Impax as Chief Scientific Officer and Senior Vice President, R&D in March 2015. In addition to developing ANDA, NDA, and 505(b)(2) products, Dr. Gupta has extensive experience in licensing, due diligence, remediation, co-development, and relationship management with external partners. Previously, he was with CorePharma as the Chief Scientific Officer and Senior Vice President, R&D where he was responsible for setting the overall strategy for its Generic and Brand R&D. Prior to that, he held positions of increasing responsibility at Mallinckrodt in St. Louis, MO; Pfizer in Chicago, IL; and Ranbaxy in New Delhi, India. Dr. Gupta served as elected Chair of the Pharmaceutical Technologies (PT) and Manufacturing Science and Engineering (MSE) Sections of American Association of Pharmaceutical Scientists (AAPS). He is a certified Six Sigma Black Belt and has published and delivered invited talks in the area of novel drug delivery and controlled release. Dr. Gupta received an Master of Business Administration in Strategy and Finance from Washington University, St. Louis, MO; a Ph.D. in Pharmaceutical Sciences from The University of Georgia, Athens, GA; a Master’s degree in Pharmaceutics from Banaras Hindu University, India; and a Bachelor’s degree in Pharmacy from Amravati University, India.

Donna M. Hughes

Senior Vice President, Human Resources

Donna M. Hughes joined Impax in May 2015 as Senior Vice President of our Human Resources group. Donna has over 20 years of legal and human resources experience and oversees all of Impax's human resource functions. Previously, she was with Actavis, where she was Vice President, Labor and Employment, and a member of Actavis' Global Leadership Team and Human Resources Leadership Team. Donna was responsible for the management of all labor and employment law matters company-wide, including employment litigation, benefits, immigration, acquisition due diligence, post-merger integration, and global human resources issues. Prior to joining Actavis, Donna served as Director and Assistant General Counsel for Circuit City Stores, Inc., where she managed the company's employment law department. She spent seven years in private practice and worked at New Jersey law firms Pitney, Hardin, LLP and St. John & Wayne, LLC. She has previously served as adjunct faculty for Rutgers University School of Management, Rutgers University's Political Science Department, and Seton Hall University School of Law. Donna received her Juris Doctorate from Rutgers University School of Law-Newark and her Bachelor's degree from Rutgers College, Rutgers University.

Deborah M. Penza

Senior Vice President, Chief Compliance Officer

Deborah M. Penza joined Impax in May 2015 as Senior Vice President, Chief Compliance Officer. Deborah has over 20 years of experience as both a consultant and a compliance professional implementing and operating compliance programs in the healthcare industry. She is responsible for the development, implementation and oversight of Impax's corporate compliance program. Previous to joining Impax, she was with Actavis as the Company’s Chief Compliance Officer. Prior to Actavis, Deborah served as the Vice President, Corporate Compliance for Elan Corporation, plc, where she led the company's global ethics and compliance program. Before joining Elan, she was a Vice President of Strategic Management Systems, Inc., where she developed and implemented compliance programs for healthcare clients and provided guidance on compliance program management. Deborah received her Juris Doctorate from the George Mason University School of Law, and she possesses a Master of Arts from The George Washington University. She received her Bachelor's degree from Florida Atlantic University.

Andrew Schaschl

Senior Vice President, Global Operations

Andy Schaschl joined Impax in March 2015 as Senior Vice President of Global Operations where he has responsibility for the internal and external product supply network of manufacturing sites and contract manufacturers. Previously, Andy was with CorePharma as Senior Vice President, Operations, overseeing Manufacturing, Supply Chain, Engineering, Technology, New Product Launches, Environmental Health and Safety, Security, and Controlled Substance Compliance.

Andy is an accomplished professional with 30 years of experience in API, solid dose, controlled substance, sterile filing and packaging, medical device and nuclear medicine manufacturing. Most recently, Andy held executive positions with Mallinckrodt Pharmaceuticals (formerly Covidien) leading its multi-site manufacturing network as well as Manufacturing Science and Technology. Prior to that, Andy was with Pfizer (formerly Wyeth) where he held senior operations and engineering leadership positions in the U.S. and internationally, which included establishing new Greenfield operations in Singapore and Ireland. Andy received his Bachelor’s degree in Chemical Engineering from the University of Connecticut.

Brandon Smith

Senior Vice President, Corporate Development and Strategy

Brandon Smith serves as Senior Vice President of Corporate Development and Strategy overseeing strategic planning, business development and licensing, alliance management, deal integration, and portfolio management for both our generic and brand businesses. Brandon joined Impax in June 2012 and has played an integral role in setting the strategic direction for the company. Prior to joining Impax, he served as executive director at Amgen responsible for biosimilars strategic planning and operations and had served in prior roles in strategy and corporate development and operations strategy. Before Amgen, he worked at the Boston Consulting Group as a project leader and at BASF in operations. Brandon has a Bachelor’s degree in Chemical Engineering from the University of Michigan and a Master of Business Administration from the University of Texas.

Board of Directors
 

Leslie Z. Benet, Ph.D.

Director

Leslie Z. Benet, Ph.D. has been a Professor since 1969 of, and has also served as Chairman of, the Department of Bioengineering and Therapeutic Sciences (1978-1998), University of California, San Francisco (UCSF). Dr. Benet has been a founder of four biopharmaceutical start-up companies, for one of which he presently serves as chair of the Scientific Advisory Board (Hurel Corp). He received his A.B. (English), B.S. (Pharmacy), and M.S. from the University of Michigan, and his Ph.D. from the University of California. Dr. Benet has received eight honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987); Leiden University, The Netherlands (Ph.D., 1995); University of Illinois at Chicago (D.Sc., 1997); Philadelphia College of Pharmacy and Science (D.Sc., 1997); Long Island University (D.Sc., 1999); University of Athens, Greece (Ph.D., 2005); Catholic University of Leuven, Belgium (Ph.D., 2010) and University of Michigan (D.Sc., 2011). In 1985, Dr. Benet served as President of the APhA Academy of Pharmaceutical Sciences. During 1986, Dr. Benet was a founder and first President of the American Association of Pharmaceutical Scientists. In 1987, Dr. Benet was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences. Dr. Benet formerly served as Chair of the FDA Expert Panel on Individual Bioequivalence and the FDA Center for Biologics Peer Review Committee, and as a member of the FDA Science Board and the Generic Drugs Advisory Committee. From 2005 through 2012, Dr. Benet served as a member of the IOM Forum on Drug Discovery, Development and Translation. Dr. Benet brings to the board deep knowledge and understanding of the biopharmaceutical industry, as well as policies and practices of the U.S. Food and Drug Administration, and provides the board with a unique perspective in the development of our corporate strategy based on his more than 40 years of experience in the science underlying our business.

Committees

  • Compensation Committee - Chair
  • Nominating Committee
  • Compliance Committee

Richard A. Bierly

Director

Richard Bierly “Rick”, most recently served as Chief Financial Officer of Medivation, Inc. Since October 2015, Rick has served on the board of directors and as chair of the audit committee of Aclaris Therapeutics, Inc. Rick has over 35 years' experience in finance roles at Glaxo-SmithKline, Aventis, Centocor and Johnson & Johnson. Among these roles were Biotechnology Chief Financial Officer, Diagnostics Chief Financial Officer, Treasurer, External Reporting Director, Head of Shared Services and operational finance roles in support of sales, marketing, supply chain and R&D. He served as Vice President of finance at Ortho Biotech LP. From 1999 to 2012, he served in several leadership roles at Johnson & Johnson, including from August 2010 to 2012, as Vice President of Global Finance Services. He served as Vice President of Finance at Centocor Inc., from August 2001 to February 2008. From October 1999 to August 2001, he served as an Executive Director of Finance at Centocor, Inc. following Johnson & Johnson’s acquisition of Centocor. From 1997 to 1998, he served as Vice President and Chief Financial Officer at Centocor Diagnostics, Inc. From 1998 to 1999, he served as Executive Director of Finance at Centocor prior to Johnson & Johnson’s acquisition of Centocor. From 1995 to 1997, he served as Vice President and Treasurer of an Aventis-Hoechst start-up joint venture in the blood plasma business. He served as an Executive Director of Ernst & Young LLP's Financial Accounting Advisory Services practice for life sciences and other clients from September 2013 to March 2014. He also held director of external reporting and other financial roles at Aventis from 1991 to 1995 and SmithKline Beecham from 1981 to 1991. Rick received his B.A. degree from Pennsylvania State University and is a certified public accountant in Pennsylvania (inactive) and New Jersey (inactive).

Committees

  • Audit Committee

Robert L. Burr

Chairman

Robert L. Burr has been a self-employed investment manager since May 2008. Mr. Burr was employed by J.P. Morgan Chase & Co. and associated entities from 1995 to May 2008, at which time he resigned his position as Managing Partner of the Fleming US Discovery III Funds. From October 2001 to October 2005, Mr. Burr was also a Partner at Windcrest Discovery Investments LLC, an investment management firm. Mr. Burr previously served as a director of Hudson Technologies, Inc., a publicly traded refrigerant services company, from 1999 to 2007. From 1992 to 1995, Mr. Burr was head of Private Equity at the investment banking firm Kidder, Peabody & Co., Inc. Prior to that time, Mr. Burr served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Mr. Burr received an MBA from Columbia University and a BA from Stanford University. Mr. Burr's financial acumen and his extensive knowledge of capital markets represent a valuable resource to the board in the assessment of our capital and liquidity needs. In addition, Mr. Burr's venture capital and private equity investment experience gives him the leadership and consensus-building skills to guide the board on a variety of matters, including compensation, corporate governance and risk assessment.

Committees

  • Audit Committee
  • Nominating Committee
  • Compensation Committee

Allen Chao, Ph.D.

Director

Allen Chao, Ph.D. has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company, since January 2008. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company's growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue. Dr. Chao's experience brings to the board a profound understanding of financial investment, business development, strategic planning and operational management in our industry and can provide invaluable practical guidance, insight and perspective with respect to our operations, strategy, and corporate governance.

Committees

  • Nominating Committee - Chair
  • Audit Committee
  • Compliance Committee

Mary K. Pendergast, J.D./LL.M.

Director

Ms. Pendergast is President of Pendergast Consulting, a firm which provides legal and regulatory consulting services to pharmaceutical and biotechnology companies and other entities, and which Ms. Pendergast founded in 2003. Before that, Ms. Pendergast served as Executive Vice President, Government Affairs for Elan Corporation, plc from 1998 to 2003. Ms. Pendergast was Deputy Commissioner and Senior Advisor to the Commissioner, Food and Drug Administration, Department of Health and Human Services from 1990 to 1998, and Associate Chief Counsel for Enforcement at FDA from 1979-1990. Ms. Pendergast is on the Board of Directors of ICON plc. She received her LL.M., J.D., and B.A. degrees from Yale Law School, the University of Iowa College of Law, and Northwestern University, respectively.

Committees

  • Compliance Committee - Chair
  • Nominating Committee

Peter R. Terreri, CPA

Director

Peter R. Terreri is President, Chief Executive Officer and director of CGM, Inc., a manufacturing company that he has owned and operated since 2000. He previously served as Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 through 2000 and as an auditor at PricewaterhouseCoopers LLP from 1981 to 1984. Mr. Terreri received his B.S. in Accounting from Drexel University and has been a certified public accountant since 1981. Mr. Terreri's more than 20 years of experience in the pharmaceutical industry provides the board with comprehensive understanding of our operations and strategy. His prior experience as Chief Financial Officer of a major generic pharmaceutical company also brings to the board deep understanding of accounting and risk management issues.

Committees

  • Audit Committee - Chair
  • Compensation Committee

 

Janet S. Vergis

Director

Janet S. Vergis has served as an executive advisor for private equity firms since 2013, where she identifies and evaluates healthcare investment opportunities. She is currently retained in that capacity by Water Street Healthcare Partners, LLC, and by Deerfield Management and previously served as an executive in residence advisor at Warburg Pincus, LLC. Prior to her advisory roles, she was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health, where she led that company's successful turnaround and subsequent sale to Valeant Pharmaceuticals International, Inc. Prior to joining OraPharma, she spent more than 21 years with Johnson and Johnson (JNJ) and its subsidiaries where she served in various positions of increasing responsibility in executive leadership including as President of Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics. During her time at JNJ and its subsidiaries, she gained significant experience in research and development, new product development and sales and marketing. Since May 2014, Ms. Vergis has been on the board of directors of Church and Dwight Co., Inc., a consumer products company. Ms. Vergis previously served as a member of the board of directors of Lumara Health (formerly K-V Pharmaceutical Company), a specialty branded pharmaceutical company from 2013 to 2014, and of OraPharma from 2011 to 2012. Ms. Vergis earned a B.S. degree in Biology and an M.S. degree in Physiology from The Pennsylvania State University.

Committees

  • Compensation Committee
  • Nominating Committee